Veradigm | MDRX - Gross Profit On Sales


Veradigm reported $83.44M in Gross Profit on Sales for its fiscal quarter ending in September of 2022.





Gross Profit On Sales Change Date
Alcidion AUD 21.02M 5.65M Dec/2025
Ambu A/S DKK 975M 27M Jun/2026
Amplifon EUR 130.09M 760.55M Mar/2026
Cardinal Health USD 2.56B 62M Jun/2026
Centene USD 13.82B 8.56B Jun/2026
Charles River Laboratories USD 348.78M 69.47M Jun/2026
Cigna USD 6.08B 50.37B Mar/2026
Coloplast 4.74B 27M Dec/2025
Convatec Group USD 660.5M 348.95M Dec/2024
CVS Health USD 15.75B 125M Jun/2026
Diasorin EUR 203M 17M Jun/2026
Elevance Health USD 44.33B 32.65B Jun/2026
General Electric Aerospace USD 4.46B 220M Jun/2026
Gulf Medical Proj AED 46.22M 8.48M Mar/2025
Humana USD 4.82B 754M Jun/2025
IQVIA Holdings USD 1.44B 368M Jun/2026
Laboratory Of America USD 1.11B 98.2M Jun/2026
Maximus USD 348.8M 6.54M Jun/2026
McKesson USD 3.68B 359M Jun/2026
Med Life RON 681.6M 53.34M Mar/2026
Molina Healthcare USD 1.43B 53M Jun/2026
Omnicell USD 152.94M 12.57M Jun/2026
Oriola-kd EUR 40.2M 2.1M Sep/2025
Owens Minor USD 272.05M 20.92M Dec/2025
Quest Diagnostics USD 906M 33M Mar/2026
Rede D'or Sao Luiz BRL 3.22B 34.56M Mar/2026
Siemens Healthineers EUR 2.14B 66M Mar/2026
Sonova Holding CHF 1.28B 205.2M Dec/2025
Supermax Corporation Bhd MYR -143.15M 161.11M Sep/2025
UnitedHealth USD 98.66B 73.25B Jun/2026
Veeva Systems USD 715.19M 36.58M Jun/2026
Veradigm USD 83.44M 3.95M Sep/2022
Xerox USD 441M 15M Jun/2025